Document is current
Any future updates will be listed below
-
Authors
Zheng, Mei-Mei
Li, Yang-Si
Tu, Hai-Yan
Sun, Hao
Yin, Kai
Jiang, Ben-Yuan
Yang, Jin-Ji
Zhang, Xu-Chao
Zhou, Qing
Xu, Chong-Rui
Wang, Zhen
Chen, Hua-Jun
Zhou, De-Xiang
Wu, Yi-Long http://orcid.org/0000-0002-3611-0258
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81802298)
Key Lab System Project of Guangdong Science and Technology Department – Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (2017B030314120)
Guangdong Provincial People's Hospital Young Talent Project (KY012021191)
High-level Hospital Construction Project (DFJH201910)
- License Information
-
More Information
Article History
Received: 24 December 2021
Accepted: 26 April 2022
First Online: 30 May 2022
Declarations
:
: Included patients from our institute provided signed informed consent and the study protocol was approved by the Research Ethics Committee of Guangdong Provincial People’s Hospital (Ethics approval ID: No. GDREC2018426H).
: Not applicable.
: Y-L Wu has received honoraria from AstraZeneca, Eli Lilly, Roche, Pierre Fabre, Pfizer, and Sanofi; consulting or advisory tole with AstraZeneca, Roche, Merck, and Boehringer Ingelheim and Roche outside the submitted work. The other authors declare that they have no competing interests.
